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In contrast to the adult brain, the adult spinal cord is a non-neurogenic environment. Under-
standing how to manipulate the spinal cord environment to promote the formation of
new neurons is an attractive therapeutic strategy for spinal cord injury and disease. The
cannabinoid 1 receptor (CB1R) has been implicated as a modulator of neural progenitor
cell proliferation and fate speciﬁcation in the brain; however, no evidence exists for mod-
ulation of adult spinal cord progenitor cells. Using adult rat spinal cord primary cultures,
we demonstrated that CB1R antagonism with AM251 signiﬁcantly decreased the number
of Nestin(+) cells, and increased the number of βIII tubulin(+) and DCX(+) cells, indica-
tive of neuronal differentiation. AM251’s effect was blocked by co-application of the CB1R
agonists, WIN 55, 212-2, or ACEA. Consistent with our hypothesis, cultures, and spinal
cord slices derived from CB1R knock-out (CB1−/−) mice had signiﬁcantly higher levels
of DCX(+) cells compared to those derived from wild type (CB1+/+) mice, indicative of
enhanced neuronal differentiation in CB1−/− spinal cords. Moreover, AM251 promoted
neuronal differentiation in CB1+/+, but not in CB1−/− cultures. Since CB1R modulates
synaptic transmission, and synaptic transmission has been shown to inﬂuence progenitor
cell fate, we evaluated whether AM251-induced neuronal differentiation was affected by
chronic inactivity. Either the presence of the voltage-dependent sodium channel blocker
tetrodotoxin (TTX), or the removal ofmature neurons, inhibited theAM251-induced increase
in DCX(+) cells. In summary, antagonism or absence of CB1R promotes neuronal differenti-
ation in adult spinal cords, and this action appears to requireTTX-sensitive neuronal activity.
Our data suggest that the previously detected elevated levels of endocannabinoids in the
injured adult spinal cord could contribute to the non-neurogenic environment and CB1R
antagonists could potentially be used to enhance replacement of damaged neurons.
Keywords: CB1R, adult spinal cord cultures, neuronal differentiation
INTRODUCTION
The cannabinoid 1 receptor (CB1R) is a G-protein coupled recep-
tor originally discovered as the speciﬁc binding cite of the major
psychoactive constituent of marijuana (cannabis). CB1R is ubiq-
uitously expressed on neurons throughout the central nervous
system primarily at pre-synaptic sites, and is activated by the
endocannabinoids AEA or 2-AG to decrease the probability of
neurotransmitter release through inhibition of voltage-dependent
calcium channels or activation of inwardly rectifying potassium
channels (Wilson and Nicoll, 2002). CB1R is also involved in
developmental processes such as proliferation, survival, and dif-
ferentiation of neural progenitor cells derived from embryonic
and adult rodent brain (Wilson and Nicoll, 2002). Though these
studies demonstrate the importance of CB1R in adult brain
neurogenesis, controversy exists regarding whether activation or
inhibition of CB1R induces neuronal differentiation of brain
progenitor cells (Rueda et al., 2002; Hill et al., 2006; Aguado
et al., 2007). The contrasting, but not necessarily conﬂicting,
results can be attributed to various factors such as chronic ver-
sus acute administration of cannabinoid drugs or thymidine
analogs, endogenous versus synthetic cannabinoid compounds,
and the patho-physiological context under which these com-
pounds are administered (Rueda et al., 2002; Galve-Roperh et al.,
2006, 2007).
Interestingly, no studies have examined CB1R’s role in neu-
ronal differentiation of adult spinal cord progenitor cells. Though
progenitors exist in the adult spinal cord, the environment is not
permissive for neurogenesis (Horner et al., 2000;Horky et al., 2006;
Barnabe-Heider et al., 2010). The ability to direct the progenitors
to a neuronal fate bymanipulating the non-permissive adult spinal
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cord environment is an attractive therapeutic strategy for spinal
cord injuries involving neuronal death. These progenitor cells have
intrinsic neurogenic potential, but they preferentially differentiate
into glial phenotypes in vivo (Weiss et al., 1996; Shihabuddin et al.,
1997, 2000; Barnabe-Heider et al., 2010). CB1R is located through-
out the spinal cord and is involved in sensory and motor functions
(Pernia-Andrade et al., 2009; ElManira andKyriakatos, 2010). The
ﬁndings of this study indicate that CB1R may also be a modulator
of progenitor cell fate in the spinal cord.
Using primary cultures from adult rats and CB1R knock-out
mice, we tested the hypothesis that CB1R antagonism/inverse
agonism with AM251 could promote neuronal differentiation
of adult spinal cord-derived progenitor cells in vitro. This study
demonstrates that adult spinal cord progenitors have intrinsic
neurogenic potential that can be revealed by manipulating the
endocannabinoid system.
MATERIALS AND METHODS
PRIMARY MIXED CULTURE OF ADULT RAT SPINAL CORD CELLS
Adult male Sprague Dawley rats aged 60–80 days were used,
weighing between 250 and 450 g and CB1+/+ (wild type)
and CB1−/− (knock-out) mice aged 6–8weeks were used for
experiments because of increased mortality of CB1−/− begin-
ning after 10weeks (Zimmer et al., 1999). All experiments were
approved by and performed in accordance with the New York
University Langone Medical Center Institutional Animal Care
and Usage Committee. Rats/mice were anesthetized with an
intraperitoneal injection containing a cocktail mixture of Ket-
amine (80mg/kg-rats/100mg/kg-mice Ketaset, Fort Dodge Ani-
mal Health, IA, USA) and Xylazine (12mg/kg, Anased, Shenan-
doah, IA, USA) and were perfused intracardially with 250ml
(rat)/125ml (mouse) artiﬁcial cerebrospinal ﬂuid (ACSF), pH 7.4
at 4˚C as previously described (Montoya et al., 2009). The ACSF
was prepared in distilled de-ionized water as follows: dextran
0.4mM, Sucrose 125mM, Glycerol 125mM, NaHCO3 26mM,
Glucose 15mM, HEPES 2.1mM, KCl 3mM, MgSO4 1.3mM,
and KH2PO4 1.2mM. The ACSF was ﬁltered and oxygenated
for 30min with 95% O2/5% CO2 prior to use. After perfu-
sion, the rat/mouse was decapitated with a guillotine, and the
spinal cord was extracted using hydraulic extrusion (modiﬁed
from Shihabuddin, 2008). The spinal column of the rat/mouse
was exposed and cut ∼4 cm (rat)/1 cm (mouse) from the base of
the tail to expose the spinal canal in the sacral region. A 10-ml
(rat)/5ml (mouse) syringe ﬁlled with ACSF and capped with a
16½ (rat)/20½ (mouse) gage needle was inserted into the spinal
canal and quickly compressed to extrude the cord from the decap-
itated cervical end. The extruded spinal cord was collected in
cold Hibernate A medium (Brain Bits, IL, USA) supplemented
with 2% B27 (Gibco), 0.5mM Glutamax (Gibco), and Peni-
cillin (100U/ml)/Streptomycin (100μg/ml; Gibco), (referred to
as “HA-complete”).
The entire spinal cord was cut into 2mm pieces and placed
into a 10-ml sterile solution of HA-complete with 0.2% papain
(Worthington) and 0.02% DNase (Worthington). The tissue was
incubated with these enzymes for 15min at room temperature
(RT) with gentle agitation, and then for 15min at 30˚C with
gentle agitation. Afterwards, the supernatant was discarded and
2ml of HA-complete with 0.02% DNase was added to the pellet.
Using three sterile ﬁre-polished pasteur pipettes of decreasing
bore size, the tissue pellet was triturated 10 times each and
allowed to settle for 1min before the supernatant was collected
into a separate tube. After each trituration, an additional 2ml
of HA-complete was added to the pellet. The resulting 6ml of
dissociated tissue was added on top of 5ml of a 6% OptiPrep
(Accurate Chemical and Scientiﬁc Corp., NY, USA) in a 50-ml
conical tube (prepared using HA medium). This was centrifuged
for 10min at 4˚C at 822× g (1700 rpm Beckman JS-4.2 rotor).
The myelin band (formed at the interface of the two fractions)
was removed using a sterile 3ml transfer pipette (Samco) and
discarded. To remove the OptiPrep from the cell suspension,
20ml of HA-complete was added and mixed thoroughly with
the cell suspension. This mixture was passed through a 70-μM
cell strainer (BD Falcon) to remove debris or tissue pieces that
were not fully dissociated, and was then centrifuged for 5min
at 480× g at 4˚C. The supernatant was discarded and the pel-
let resuspended in 3ml of HA-complete. An Optiprep gradi-
ent was then prepared and consisted of the following fractions:
from bottom to top, 12, 9, 7.4, 6, 4.8%, 2ml each in a 15-
ml conical tube. The different fractions were with Hibernate A
medium supplemented with 2% B27 and either pure OptiPrep
or OptiPrep stock as follows. OptiPrep stock (10ml) was made
by mixing 4.95ml of pure OptiPrep with 5.05ml HA medium.
For the fractions 4ml of each were made: 12% – add 0.8ml
pure OptiPrep to 3.2ml of HA medium; for 9% – add 0.6ml
pure OptiPrep to 3.4ml HA medium); for 7.4% – add 1ml stock
OptiPrep to 3ml of HA medium; for 6% add 0.8ml OptiPrep
Stock to 3.2ml of HA medium and ﬁnally, for 4.8% – add
0.6ml of stock OptiPrep to 3.4ml of HA medium. The gradient
was prepared by adding 2ml of each fraction in a 15-ml con-
ical tube, and then adding 3ml of the cell suspension to the
top of the gradient. The gradient was centrifuged for 15min
at 480× g and 4˚C. The 12%, 9%, and 7.4% fractions were
collected into separate 15ml tubes. The volume of each frac-
tion was brought up to 5ml with HA-complete, mixed well,
and centrifuged for 5min at 480× g and 4˚C to dilute out the
OptiPrep and obtain a pellet of cells. After the centrifugation,
the pellets were resuspended separately with warm Neurobasal
A medium supplemented with 2% B27 (Gibco), 0.5mM Gluta-
max (Gibco), 100U/ml Penicillin, and 100μg/ml Streptomycin
(Gibco) and then pooled. The ﬁnal volume for all the frac-
tions was ∼500μl. The total cell yield in each experiment was
∼250,000 cells (500,000 cells/ml), and 10μl of the cell suspen-
sion was plated onto poly-d-lysine coated coverslips (Sigma,
50μg/ml). The cells were incubated for 1 h at 37˚C/5% CO2
to attach before additional media with or without drugs was
added. Unless otherwise indicated, the culture medium (growth
media) consisted of Neurobasal A medium supplemented with
B27 (2%), Glutamax (0.5mM), Penicillin (100U/ml), Strepto-
mycin (100μg/ml), a growth factor mixture [Glial Derived Neu-
rotrophic Factor (Chemicon; 0.1 ng/ml); Ciliary Neurotrophic
Factor (Sigma; 10 ng/ml); brain derived neurotrophic factor
(Invitrogen; 1 ng/ml), and cAMP analog 8-(4-Chlolorophenyl-
thio) cyclic adenosine-3′,5′-cyclic monophosphate sodium salt
(Sigma C3912)], and 30% muscle conditioned medium that was
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prepared using amuscle cell line as previously described (Montoya
et al., 2009).
CULTURES ENRICHED FOR PROGENITORS FROM ADULT RAT SPINAL
CORD CELLS
The cell isolation was done exactly as described above, except
that the media consisted of Neurobasal A medium supple-
mented with only B27 (2%), Glutamax (0.5mM) Glutamax, Peni-
cillin (100U/ml), Streptomycin (100μg/ml), and basic ﬁbroblast
growth factor (bFGF; Invitrogen; 20 ng/ml).
DRUGS
All drugs were purchased from Tocris USA (WIN 55, 212-2;
AM251; ACEA) and dissolved in either sterile DMSO (Dimethyl
Sulfoxide; Sigma) or absolute Ethanol. On days 0, 1, 3, and 5 in
culture, 75% of the growth media was removed and replaced with
fresh media treated with either a vehicle (DMSO or ethanol), a
cannabinoid receptor agonist (WIN55,212-2,orACEA),an antag-
onist (AM251), or a mixture of agonist and antagonist. For the
experiments in Figures 4C–E, only 50% of media was removed.
When performing the concentration–response experiments, the
apparent potency of AM251 was higher if the feeding protocol
involved removal of 75%, instead of 50%, of the old media, prob-
ably reﬂecting drug dilution in our cultures. We also observed
that the potency of AM251 decreased over time while stored at
−20˚C, but nevertheless a range of efﬁcacy for inducing neuronal
differentiationwas observedbetween10 and500 nM.For all exper-
iments, different stock solutions were made so that the volume of
drug added into each well and the ﬁnal vehicle concentration was
the same.
GENOTYPING CB1R TRANSGENIC MICE
The genotyping protocol was kindly provided by Dr. Rui Costa
from the InstitutoGulbenkiandeCiencia,Portugal [personal com-
munication, and for reference (Hilario et al., 2007)]. The kit used
for DNA extraction and PCR was Sigma PCR kit, and the com-
pany protocol was followed,with slightmodiﬁcations. Brieﬂy, each
tail snip was incubated at RT with Extraction and Tissue Prepara-
tion mixture for 12min. The samples were then placed in boiling
water for 3min. Immediately afterward, Neutralization solution
was added to the samples, the tubes vortexed for 3 s, and kept on ice
until the“MasterMix”PCRmixturewasmade.A“MasterMix”was
made with Extract-N-Amp solution (Sigma), DNAse free water,
primers, and DNA extract. Primers were obtained from Integrated
DNATechnologies, and dissolved in distilled, de-ionized water at a
100-μM stock concentration, and at 5μM working solution con-
centration, all stored at −20˚C. A ﬁnal concentration of 400 nM
of each of the following primers was used in the PCR reaction,
Forward: GTA CCA TCA CCA CAG ACC TCC TC, Wild Type:
GGA TTC AGA ATC ATG AAG CAC TCC A, Knock-out: AAG
AAC GAG ATC AGC AGC CTC TGT T (Costa et al., 2005). A 1%
agarose gel was made in 1× TAE buffer, with SYBR Safe DNA Gel
Stain (Invitrogen). Samples were electrophoresed in TAE buffer at
100V using an EPS250 power supply (C.B.S. Scientiﬁc Company,
Inc.) for ∼40min. The gel was visualized under UV light and an
image of the gel acquired. Amplicon size for the CB1+/+ mice
was 300 bp, for CB1−/− was 160 bp, and CB1+/− contained both
bands.
SPINAL CORD SLICE PREPARATION
Spinal cord slices of adult CB1+/+ and CB1−/− mice were pre-
pared and stained with DCX following the protocol described by
Shechter et al. (2010). As a control, ﬁve times excess of the DCX
blocking peptide (Santa Cruz cat# sc-8066 P) was incubated with
the primary antibody.
IMMUNOCYTOCHEMISTRY
Two hours after plating the cells, or after 6 days in culture,
the cells were washed [two times for 2min each, with phos-
phate buffered saline (PBS) that was pre-warmed to 37˚C], ﬁxed
with 4% paraformaldehyde (EM Sciences) for 15min at RT, and
then rinsed with PBS three times. The cells were permeabilized
with 0.3% Triton X-100 (Sigma) for 15min at RT, then rinsed
three times with PBS. Then the cells were blocked for 1 h at
RT using 10% normal goat serum, NGS-(Sigma) in PBS. For
co-labeling, the following antibodies were used by diluting in
2% NGS and incubating overnight at 4˚C: polyclonal anti-CB1R
(1:500 Thermo Scientiﬁc #PA-743); monoclonal anti-Tu-20 (βIII
tubulin isoform 1:1000 Millipore cat # MAB1637); or polyclonal
Doublecortin-DCX (1:250 Santa Cruz cat # sc-8066). Two Nestin
antibodies were used: polyclonal anti-Nestin (1:1000 Abcam cat
# ab5968, lot#122206, we found that lot #575937 gave too high
of a background and hence were not used) and the monoclonal
anti-Nestin (1:200 Millipore cat # MAB353). After primary anti-
body incubation, the cells were rinsed three times with PBS,
and incubated with the appropriate secondary antibodies for
1 h in the following concentrations: Alexa-Fluor 546 goat anti-
mouse (1:1000 Molecular Probes cat #A11030), Alexa-Fluor 488
goat anti-rabbit (1:1000 Molecular Probes #A11034). After rins-
ing with PBS, Hoechst (20μg/ml Sigma) was added for 20min
at RT to stain nuclei. For experiments to determine prolifera-
tion, Click-iT EdU™(5-ethynyl-2′-deoxyuridine; Invitrogen) was
used according to the manufacturer’s protocols. EdU was added
to the cultures at a concentration of 5μM (higher concentra-
tions were toxic) for ∼20 h and then identiﬁed using the Click-iT
technique. For all staining, negative controls were coverslips that
did not have any primary antibody, but only received secondary
antibodies.
WESTERN BLOT
For Western blots 1× 106 cells (E17 rat hippocampal neurons,
courtesy of J. J. Sutachan, NYU Medical Center), were plated on
poly-d-lysine coated Petri dish (35mm diameter) and cultured
for 48 h. Adult rat hippocampus, and adult rat lumbar spinal
cord were isolated, frozen on dry ice, and stored at −80˚C until
protein isolation. For protein extraction, dishes were placed on
ice and washed ﬁrst with 1.0ml of cold PBS (containing Ca2+
and Mg2+) and a second time with 1.0ml of cold PBS (with-
out Ca2+ and Mg2+) plus 5μl of a protease inhibitor cocktail
(PIC; Pierce, Thermo, Fisher Scientiﬁc Inc., Rockford, IL, USA,
cat # 78410) for 5min each. Then 50–55μl of RIPA lysis buffer
(Millipore, Billerica, MA, USA), 0.1% SDS, and PIC (1:66) were
added to each of the Petri dishes and left on ice for 30min.
Samples were detached with a cell scraper, collected, vortexed (5–
7 s), left on ice (30min), and centrifuged (14,000g, 15min, 4˚C).
The supernatant was collected, aliquoted, and stored at −80˚C.
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Protein concentrations were determined using the Lowry Assay
(Sigma Aldrich). The sample volume containing 20μg of pro-
tein was brought to a volume of 15–25μl by adding RIPA and
3–5μl of loading buffer 5× was added (Crystalgen Inc., Com-
mack, NY, USA). The protein was denatured (boiling, 5min) and
loaded onto a 4–20% gradient (Invitrogen, #EC6025) SDS-PAGE
gels. Electrophoresis was carried out (120–150min, Power sup-
ply Model-EPS-250-CBS Scientiﬁc Company, Del Mar, CA, USA,
set at ∼25mA) in 1× running buffer (from 10× Tris Gly–SDS
electrophoresis solution, Fisher Scientiﬁc, Pittsburgh, USA). The
protein was transferred onto Amersham Hybond-P polyvinyli-
dene diﬂuoride (PVDF)membranes (GEHealthcare,USA). PVDF
membranes were incubated/activated in 100% methanol (2min),
rinsed with dH2O (5min), and equilibrated in transfer buffer
(10min, RT). A“sandwich”containing sponge-ﬁlter paper, the gel,
and the membrane was made and protein transfer was performed
(2 h,∼100V; Power supply Model-EPS-250-CBS Scientiﬁc Com-
pany, Del Mar, CA, USA). Proteins were visualized by placing the
membrane in Ponceau S solution (Sigma) for 5min. The non-
speciﬁc binding sites were blocked by incubating the membrane
(90min, RT) with either 5% non-fat dry milk (Lab Scientiﬁc, Liv-
ingston, NJ, USA) in 0.1% PBST (PBS containing 0.1% Tween
20). The membrane was incubated with monoclonal anti-Tu-20
[βIII tubulin isoform (1:3000 Millipore) overnight with gentle
agitation, 4˚C]. The primary antibody was diluted in 3% non-
fat dry milk. Blots were washed four times for 5min with 0.1%
PBST and incubated with a goat anti-mouse secondary antibody
(Santa Cruz Biotechnology 1:5000, cat # sc-2005) for 90min at
RT with agitation. Blots were then extensively washed accord-
ing to the manufacturer’s instruction and developed using the
ECL detection method (SuperSignal West Pico, Thermo Scien-
tiﬁc #34077, or the SuperSignal West Dura, Thermo Scientiﬁc
#37071).
IMAGE ACQUISITION AND ANALYSIS
Images for quantiﬁcation were acquired using a Zeiss Axiovert
200 microscope by sampling either 20 or 40 random ﬁelds in three
coverslips per treatment. Pictures of negative controls were also
taken at the same exposure time as the positive coverslips, and
used to determine the background intensity values. Image acqui-
sition for initial experiments (Figures 4C–F) was performed by
blinding the investigator to the different treatments. Positive cells
were counted by eye after subtracting the background. For all other
experiments, every cell per image (for all treatments) was traced
and the ﬂuorescent intensity was generated using Axiovision soft-
ware. The average background intensity values from the negative
controls were used to determine the ﬂuorescence intensity cutoff
value above which the cells would be considered “positive” for the
antibody. A cell was considered positive for a marker if the inten-
sity value of the ﬂuorophore was 3 standard deviations above the
mean background value determined from the negative controls.
Statistical analysis was done using either one-way ANOVA with
Bonferroni’s (for comparisons of three to ﬁve groups) or Dun-
nett’s (when more than ﬁve groups, and all the treatment groups
were compared to the control) multiple comparison post-tests, or
using the Unpaired t -test for comparison of two groups. Paramet-
ric tests were chosen because we determined that the distributions
(number of cells versus labeling intensity) of Nestin(+) cells
(in mixed- and progenitor-enriched cultures); and of DCX(+)
cells (in progenitor-enriched cultures) were consistent with that
of a Gaussian distribution (D’Agostino–Pearson–omnibus K2,
normality test, Prism; p> 0.7).
RESULTS
CB1R IS PRESENT ON VARIOUS ADULT SPINAL CORD CELLS,
INCLUDING PROGENITORS
Because the goalwas to determine the role thatCB1Rplays inmod-
ulating the fate of the progenitors, the presence of the receptor
was determined in our two cell populations of interest: neural
progenitors and immature neurons. Nestin was used as a neural
progenitor marker (Hockﬁeld and McKay, 1985; Gritti et al., 1996;
Weiss et al., 1996) and βIII tubulin as an immature neuronal
marker (Lee et al., 1990; Kehl et al., 1997). The relative propor-
tions of these populations were also assessed at two different time
points, in basal growth conditions. At Day 6, the percentage of
Nestin(+) cells in mixed cultures was 24% (±3 SEM, n = 8 cover-
slips from three separate preparations) and most were positive for
the CB1R (Figures 1A,B in mixed cultures,Figure 1C, progenitor-
enriched cultures). In these progenitors, CB1Rs were located on
the somata (Figures 1A,C), but were also observed at the ter-
minals of the progenitor extensions (Figure 1C, middle panel,
insert). Furthermore, the progenitor cells in the mixed cultures
were dividing because 8.0% (±1.5, n = 10 coverslips) co-labeled
with Nestin and EdU, accounting for ∼82% of all the Nestin(+)
cells (Figures 1D,E).
On Day 6,most of the cells (>90%) in the small cell population
that expressed the immature neuronal marker βIII tubulin also
expressed the CB1R (Figure 2A). The staining pattern for CB1R
appeared punctate and localized to the soma (Figure 2B), and was
occasionally found on the growth cones and the neurites of these
immature neurons (Figure 2B, white box,Figure 2D respectively).
In mixed cultures we found that at Day 0 ∼56% (±6.3 SEM,
n = 3) of the cells expressed CB1R, while at Day 6 ∼70% (±9.3
SEM, n = 3) of the cells expressed CB1R (Figure 2C), indicating
that mature cells, immature neurons, and progenitors from the
adult spinal cord express CB1R.
AM251 INDUCES AN INCREASE IN βIII TUBULIN POSITIVE CELLS IN A
CONCENTRATION-DEPENDENT, BIPHASIC MANNER
The CB1R speciﬁc antagonist AM251 was administered to the
mixed spinal cord cultures at various concentrations, and the
amount of βIII tubulin(+) immature neurons cells was quantiﬁed.
AM251-induced an increase in the percentage of βIII tubulin(+)
cells relative to control, with the maximal increase between 10
and 30 nM (Figure 3A). At higher concentrations (>100 nM)
the neurogenic effect induced by AM251 was lost (Figure 3A).
AM251’s effect was also occasionally detected at higher concen-
trations (100–500 nM), but this is attributable to different feeding
protocols, and adecrease in the drug’s potency over time (seeMate-
rials and Methods). The different percentages of βIII tubulin(+)
cells did not reﬂect a selective cell death because the total cell
number in the cultures did not change when exposed up to 3μM
AM251 (Figures 3B,E).Moreover, in the concentration range used
for the experiments, AM251 did not change the percentage of
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FIGURE 1 |The cannabinoid 1 receptor is present on progenitor cells
derived from adult spinal cords. (A) Mixed cultures on Day 6
immunostained with an anti-CB1R (green) and with polyclonal Nestin
(red). Individual images (Top) and the merged image (middle left). The
negative control, without primary antibody, is shown in the bottom panel.
(B) Mean number of cells that were positive (+) for the CB1R and/or
Nestin. Sixteen to twenty ﬁelds were analyzed per coverslip (n =3
coverslips; mean+SEM). Most of the Nestin(+) cells were CB1R(+), and
no signiﬁcance difference was found between the number of
CB1R(+)/Nestin(+) and CB1R(+)/Nestin(−) cells ($p<0.01, One-way
ANOVA, Bonferroni post test). (C) Primary neurospheres generated under
proliferative conditions (adding only bFGF) for 6 days, and then plated on
poly-D-lysine coated coverslips. They were immunostained with the CB1R
antibody (green), and monoclonal Nestin (red). Individual images (Top) and
merged image (middle). The inset in the middle panel corresponds to the
area outlined with the white box. For the inset the light picture is also
overlapped to facilitate visualization of the cell extension. The inset shows
CB1R labeling (green) at the end of an extension from a Nestin(+) (red)
cell. The negative control is shown in the bottom panel. (D) Percentage of
Nestin(+) cells in the entire population and of EdU(+) cells within the
Nestin(+) population in mixed cultures on Day 6. Twenty ﬁelds were
analyzed per coverslip (n =10 coverslips; mean+SEM). (E) Mixed
cultures on Day 6 immunostained with anti-Nestin (red) and labeled with
the mitogenic marker EdU (green). (A,C,E)The background ﬂuorescence
was subtracted from the image relative to the negative control. Nuclei
were labeled with Hoechst 3392 (blue). Images were acquired with a 20×
objective; scale bars=10μm.The image was selected to show a large
number of Nestin(+) cells.
MAP2(+) mature neurons, indicating that the drug treatment was
not neurotoxic (Figure 3C). The typical morphology of cultured
spinal cord cells can be seen in Figure 3D, in which the progenitors
[Nestin(+) cells] and newly generated neurons [βIII tubulin(+)
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FIGURE 2 | Cannabinoid 1 receptor is expressed on immature spinal
cord-derived neurons. (A)Total number of cells that were CB1R(+) and/or
βIII tubulin(+) in mixed cultures on Day 6. All of the βIII tubulin(+) cells were
also CB1R(+). There were more CB1R(+)/tubulin(−) cells than
CB1R(+)/tubulin(+) cells (#p<0.001, one-way ANOVA Bonferroni post test).
Twenty ﬁelds were analyzed per coverslip with a 40× objective (n =3
coverslips; mean+SEM). (B) Mixed cultures on Day 6 immunostained with
an anti-CB1R (green) and with anti-βIII tubulin (red). The terminal of the
neurite of a βIII tubulin(+) cell is also CB1R(+) (white box). (C) Percentage
of all cells that express the CB1R in mixed cultures. Cells were
immunostained with the CB1R antibody at Day 0 (2 h after plating) and at
Day 6 after culturing with growth media. There was no signiﬁcant change in
the% of CB1R(+) between Day 0 and Day 6 (Unpaired t -test, two tailed).
Twenty ﬁelds were analyzed per coverslip (n =3 coverslips; mean+SEM).
(D)This image shows one cell that is CB1R(+)/βIII tubulin(+) (immature
neuron) and another cell that is CB1R(+)/βIII tubulin(−) (which based on
morphology could represent a mature neuron). The insets in the upper left
panel (starting from the most left inset, and going in a clockwise direction)
magnify the CB1R expression on the soma/extension of the immature
neuron, the terminal of the mature neuron, and the soma/extension of
mature neuron. In all cases the background ﬂuorescence was subtracted
from the image relative to the negative control, the nuclei were labeled
with Hoechst 3392 (blue). (B,D) Images were acquired with a 63×
objective; scale bars=10μm.
cells] have small rounded bodies that are less than 10μm in
diameter. AM251 became cytotoxic at 10μM (Figure 3E). The
neurogenic effect of AM251 appears to be biphasic within a con-
centration range that does not affect the total cell number and
gross cellular morphology.
AM251 DECREASES THE PERCENTAGE OF NESTIN(+) NEURAL
PROGENITORS, WHILE INCREASING THE PERCENTAGE OF IMMATURE
NEURONS
Adult spinal cord extracts contain βIII tubulin (Figure 4A, lane
1). Consistent with the idea that the βIII tubulin population
represents newly generated immature neurons is the demonstra-
tion that a proportion of them were also capable of incorpo-
rating EdU (Figure 4B). We also used Doublecortin (DCX), a
marker that has recently been used in the spinal cord to identify
newly generated neurons (Shechter et al., 2007, 2010; Marichal
et al., 2009) and found that about half of the βIII tubulin(+)
cells also co-labeled with DCX in adult rat spinal cord cultures
(Figure 4C).
As expected, the βIII tubulin(+) cell population was low on
Day 0 (Figures 3A and 4D). The addition of AM251-induced neu-
ronal differentiation, as demonstrated by a signiﬁcant increase in
the percentage of all the cells expressing βIII tubulin from Day
0 to Day 6, (Figures 4D,E). Further characterization of these
populations, revealed that AM251 produced an increase in the
percentage of the βIII tubulin(+)/Nestin(−) cells and a decrease
in the percentage of the βIII tubulin(−)/Nestin(+) population
(Figures 4E,G). This effect was mostly abrogated by a mixed CBR
agonist, WIN 55, 212-2 (Figures 4D,E,G), and a highly speciﬁc
CB1R agonist ACEA (Figure 4F).
GLOBAL DELETION OF CB1R MIMICS PHARMACOLOGICAL INHIBITION
Cultures from wild type (CB1+/+) and CB1R knock-out
(CB1−/−) animals on Day 0 indicated that DCX was expressed
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FIGURE 3 | Biphasic concentration–response of AM251 for inducing
neuronal differentiation without affecting the total number of cells.
(A) In mixed cultures, cells were treated with increasing concentrations of
AM251. Cells were fed every other day by replacing 75% of the culture
medium. βIII tubulin(+) cells were quantiﬁed and expressed as a
percentage of the total number of cells counted. Twenty to forty ﬁelds
were analyzed per coverslip (n)=# coverslips from four separate
experiments; mean±SEM). Concentration–response curve was
generated from four separate experiments. *p<0.05 Between the group
and the untreated group at Day 6. Using the bell-shaped curve function in
Graph Pad Prism 5, the following equation was used: y =Max+ [(α−Max)/
(1+10∧((εup − x )*nH1))]+ [(ω−Max)/(1+10∧((x − εDn)*nH2))], where Max
represents the plateau level in the middle of the curve; α and ω represent
the plateaus on the left and right sides of the curve, respectively; εup is the
logEC50 and εDn is the logIC50, the concentrations that give half maximal
stimulatory and inhibitory effects, respectively; and nH1 and nH2 are the
Hill slopes. This curve approximates an EC50 of 7.5 nM, and an IC50 of
32 nM. (B). The mean total number of cells from 40 ﬁelds were analyzed
per coverslip (40× objective); n =# coverslips from ﬁve separate
experiment; mean+SEM (For each experiment the individual values were
normalized to the mean value of the untreated group at Day 6). No
signiﬁcance difference was found between any of the treated groups and
the untreated group at Day 6. (C)The percentage and MAP2(+) neurons
remains constant, regardless of the concentration of AM251 used; n =4
coverslips, except for Day 0 in which there were two coverslips. No
signiﬁcance difference was found between any of the treated groups and
the untreated group at Day 6. For (A–C) we used One-way ANOVA,
Dunnett post test. (D) Representative images of the culture with 30 nM
AM251. βIII tubulin(+) immature neurons (red), Nestin(+) neural
progenitors (green), and βIII tubulin(+)/Nestin(+) neuronal progenitors
(yellow). Images were obtained with a 20× objective; Scale bars, 10μm.
(E) Representative images of the cultures at different concentrations of
AM251 are shown. Cytotoxicity is apparent at 10μM. Images obtained
with a 10× objective; scale bars=10μm.
in 2.1% (±0.8%) of cells in CB1+/+ cultures versus 26.2%
(±5.3%) of cells in CB1−/− cultures, (n = 9 coverslips, n = 3
mice, p< 0.0004; Figures 5A,B left panels). Furthermore, the
mean number of DCX(+) cells was signiﬁcantly different between
the genotypes (at Day 0; CB1+/+: 3± 2 cells versus CB1−/−:
35± 6 cells, p< 0.01). The difference in percentage did not reﬂect
a difference in cell attachment of acutely isolated cells, or on
survival within 2 h of plating because the mean number of total
cells was comparable between the two genotypes (Figure 5C, left
panel).
On Day 6, with basal growth conditions (growth media only),
the percentage of cells expressing DCX was, again, higher in the
CB1−/− cultures compared to CB1+/+ cultures (23.1± 4.3%
versus 6.1± 0.8% SEM.; n = 9 coverslips for each genotype, n = 3
separate mice; p< 0.0003; Figure 5A right panels). Like in Day 0
cultures, this difference in percentage did not reﬂect a difference in
cell survival over the culturing period because the mean number
of cells was comparable between the two genotypes (Figure 5C
left panel). Furthermore, the same signiﬁcant difference in the
mean number of DCX cells was observed between genotypes on
Day 6 (Day 6 CB1+/+: 7± 1 cells versus Day 6 CB1−/−: 27± 4
cells). As previously reported (Shechter et al., 2007, 2010;Marichal
et al., 2009) the adult spinal cord slices from wild type animals had
DCX(+) cells (Figure 6 top). In addition,we found that themedial
regions (next to the central canal) of spinal cord slices derived
from CB1−/− mice had signiﬁcantly higher levels of DCX(+)
cells compared to those derived from theCB1+/+mice (Figure 6).
Collectively, the data show that neuronal differentiation is not only
enhanced by antagonism/inverse agonism, but also as a result of a
global deletion of CB1R.
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FIGURE 4 | Blocking CB1R enhances the expression of βIII tubulin and
decreases the expression of Nestin in adult spinal cord mixed cultures.
(A)The western blot shows that the antibody for βIII tubulin that was used
in this study, only recognizes one band in the adult spinal cord (lane 1), adult
brain (lane 2) and in cultured embryonic hippocampal cells (lane 3) at the
molecular weight expected for βIII tubulin (50 kDa). (B) Adult spinal cord
cultures were treated with 1μM of EdU between Days 1 and 2, with or
without 100 nM AM251. The cells were ﬁxed on Day 6. The low proportion
of βIII tubulin(+)/EdU(+) cells likely reﬂects the small proportion of cells that
are undergoing division between Day 1 and Day 2 ($p<0.01,*p<0.05
Unpaired t -test, one tailed). Ten ﬁelds were analyzed per coverslip (n =3
coverslips; mean+SEM). (C) After 6 days in vitro under basal growth
conditions, about 50% of the adult spinal cord-derived βIII tubulin immature
neurons also express Doublecortin-DCX (green) (n =3 coverslips;
mean+SEM). **p<0.10, One-way ANOVA, Bonferroni post test. (D,E)
Cells were grown in either the presence of vehicle DMSO, 500 nM AM251,
or 500 nM AM251 with 500 nM ofWIN 55, 212-2. The cultures were
fed/treated every other day by replacing 50% of the culture medium. At
Day 6, cells were ﬁxed and immunostained with anti-βIII tubulin (black
bars), and with a monoclonal Nestin antibody (white bars). Forty randomly
chosen ﬁelds were analyzed per coverslip (n =6 coverslips from two
separate experiments; exceptWIN, n =5; mean+SEM) taken with a 20×
objective. (E)The percentage of cells expressing only βIII tubulin and only
Nestin at Day 6 (n =3 coverslips) from one of the experiments used in
(D,E). *p<0.05; #p<0.001, $p<0.01With respect to the control DMSO
group at Day 6; and in (E) @p<0.01 with respect to the AM251 group
(one-way ANOVA, Bonferroni post test). (F) In a different experiment, the
number of cells expressing βIII tubulin were counted in the entire coverslip
treated with either vehicle 0.2% DMSO, Absolute Ethanol, 100 nM AM251,
or 10 nM ACEA; n =3 mean+SEM for all the groups, except for AM251 in
which there were 2 coverslips; mean+ range. #p<0.001With respect to
the DMSO group (one-way ANOVA, Dunnett post test). (G) Representative
images of cells at Day 6 grown in either the presence of vehicle DMSO,
500 nM AM251, or 500 nM AM251 with 500 nM ofWIN 55, 212-2. Stained
with anti-βIII tubulin (red), and with a polyclonal Nestin antibody (green).
Scale bars=20μm.
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FIGURE 5 | Comparison of percentages of DCX(+) cells at Day 0 and
Day 6 between CB1+/+ and CB1−/−spinal cord cultures. (A)
Percentage of DCX(+) cells in mixed cultures derived from CB1+/+ (wild
type, Black bars) and CB1−/− (CB1R knock-out, Gray bars) animals. Twenty
ﬁelds per coverslip; n =9 coverslips from three mice per genotype.
Signiﬁcant differences between CB1+/+ and CB1−/− groups are evident
at both time points. Under basal growth conditions, there was a modest
increase in the percentage of DCX(+) cells in CB1+/+ cultures from Day 0
to Day 6, whereas in CB1−/− cultures the high percentages of DCX(+)
cells remained unchanged during the same period. *p<0.003,
**p<0.0003, ***p<0.0004 (Unpaired t -test, two tailed). Twenty ﬁelds
were analyzed per coverslip (n =9 coverslips, from three different animals;
mean+SEM). (B)Typical morphology of spinal cord cells at Day 0 (left
panels), 2 h after plating-small rounded somata, with occasional extensions,
and of spinal cord cells at Day 6 (right panels) with growth media. Nuclei
(blue); immunostained with anti-DCX (red) and the nuclei stained with
Hoechst 3392. At Day 0, a ﬁeld of CB1+/+ cultures showing no DCX(+)
cells (top left panel) while a ﬁeld in CB1−/− cultures showing many DCX(+)
cells (bottom left panel). At Day 6, a ﬁeld of CB1+/+ cultures showing a few
DCX(+) (top right panel) and a ﬁeld in CB1−/− cultures showing a large
number of DCX(+) (bottom left panel). All images are merges of
Hoechst/DCX/DIC light picture, and were corrected for background.
(Continued )
FIGURE 5 | Continued
Images obtained with 20× objective; Scale bars=10μm. (C) Average
number of total cells per genotype on Day 0 and Day 6 quantiﬁed as the
mean number of Hoechst+ cells in 20 ﬁelds per coverslip; n =12 and 11
coverslips for Day 0 and Day 6, respectively, from three mice per genotype.
Left panel shows the raw data (Mean # of cells per 20 ﬁelds). The right
panel shows the same data normalized to its mean value at Day 0 (for each
experiment). Whether using the raw data or the normalized data, no
signiﬁcant difference was found in the number of cells between Day 0 and
Day 6 in either genotype (Unpaired t -test, two tailed).
NEURONAL DIFFERENTIATION INDUCED BY AM251 IS REVERSED BY
THE VOLTAGE-DEPENDENT SODIUM CHANNEL BLOCKER
TETRODOTOXIN (TTX)
Since there have been many studies characterizing CB1R’s neu-
romodulatory role, it was hypothesized that our observed effect
mediated by AM251 may be due, in part, to the drug’s ability
to facilitate neurotransmitter release in the spinal cord cultures,
which affects neuronal activity in vitro. If AM251’s facilitation
of neurotransmitter release drives neuronal differentiation, then
blocking neuronal activity may abrogate AM251’s effect. This
hypothesis was tested in wild type cultures treated with AM251,
with and without TTX (1μM), and any increase in the DCX(+)
cell number induced by AM251 was expected to be abolished by
TTX. Treatment with TTX was started at Day 0, to ensure that
neuronal activity would be inhibited throughout the period that
the cells were exposed to AM251. On Day 6, AM251 caused a sig-
niﬁcant increase in the percentage of DCX(+) cells compared to
Day 6 DMSO controls (Figure 7A) which did not occur in the
presence of TTX (Figure 7A). The percentage changes did not
reﬂect differences in total cell numbers, since they are comparable
across treatment groups on Day 6 (Figures 7B,C).
While AM251 was able to induce an increase in the number of
DCX(+) cells in CB1+/+ cultures (Figure 7A), it was not able to
do so in CB1−/− cultures (Figure 7D), supporting the speciﬁcity
of AM251’s effect via modulation of CB1R. Moreover, the high
level of DCX(+) cells in CB1−/− cultures was not affected by
treatment with TTX (Figure 7F). There was no signiﬁcant change
in the total number of cells on Day 6, with or without treatment
(Figure 7G). Though in individual experiments, the total cell num-
ber from Day 0 to Day 6 can show either no change or a decrease
(e.g., Figures 7B,G but not Figure 7E), the pooled data from three
separate experiments showed that there was no signiﬁcant change
in the total cell number from Day 0 to Day 6 in either genotype
(Figure 5C).We consistently observed,however, thatCB1+/+ cul-
tures have a lower % of DCX(+) cells at Day 0 and at Day 6 than
CB1−/− cultures (Figure 5A).
We speculate that since at Day 0, there are very high levels
of DCX(+) cells (and are therefore already committed to a neu-
ronal fate), neuronal activity changes induced by administration
of TTX in vitro does not affect the differentiation of the progenitor
cells.
AM251 DOES NOT INDUCE NEURONAL DIFFERENTIATION IN SPINAL
CORD CULTURES ENRICHED FOR PROGENITOR CELLS
It is not clear howAM251 exerts its apparent pro-neurogenic effect.
CB1R is present on the Nestin(+) progenitor cells, but also on
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FIGURE 6 | Spinal cords derived from CB1−/−have more DCX(+)
cells compared to those derived form CB+/+ animals. Spinal cord
sections (6μm thick) were treated with anti-DCX in the presence (ﬁrst
panels) or absence (middle panels) of the blocking peptide. The third
panels show Hoechst nuclear staining for the middle images. Images
were acquired in the medial region of the spinal cord (next to the
central canal), with a 40× objective by using the Zeiss ApoTome
system, and represent three (1μm thick) compressed consecutive
images. Scale bars=20μm, cc= central canal. Graph: mean number
of DCX(+) cells per 115μm3; n =6 measurements (from three slices);
and eight measurements (from four slices) of CB1+/+ and CB1−/−
mice.
other mature spinal cord cells. It is possible that AM251 modu-
lates the fate of the progenitors by directly antagonizing CB1R on
the progenitors, or as an indirect consequence of blocking CB1Rs
on mature spinal cord cells. The latter was suggested by the exper-
iments in which blocking neuronal activity with TTX abrogated
AM251’s neurogenic effect (Figure 7A). To further investigate the
contribution of non-progenitor cells in neuronal differentiation
mediated byAM251,we tested the action of AM251 in progenitor-
enriched cultures generated with bFGF (as described in Materials
and Methods).
Enrichment of adult spinal cord-derived progenitor cells was
conﬁrmed by the expression of Nestin, and the incorporation
and co-labeling with the proliferation marker EdU. Compared
to mixed cultures, enrichment using bFGF raised the percentage
of Nestin(+) cells to ∼70% (Figure 8A). These progenitors were
actively dividing because ∼60% of the cells that were Nestin(+)
cells also co-labeled with EdU (Figure 8A).
Under control conditions (either ±bFGF, but no drugs), the
progenitor-enriched cultures contained ∼60–80% DCX(+) cells
(Figure 8B, left panel, open bars). The levels of βIII tubulin(+)
cells were lower (Figure 8B, right panel, open bars), but compara-
ble to those in mixed cultures, indicating that bFGF itself enriches
for DCX(+) neuronal progenitor cells. Addition of AM251 and/or
growth media (see Materials and Methods) did not signiﬁcantly
change the DCX levels (Figure 8B, left panel, black bars), but
decreased the amount of cells expressing βIII tubulin (Figure 8B,
right panel, black bars). Taken together, the addition of AM251
did not induce neuronal differentiation under proliferative or
non-proliferative conditions (±bFGF, respectively) in progenitor-
enriched cultures. The results obtained here indicate that concen-
trations of AM251 that were able to promote neuronal differen-
tiation in mixed spinal cord cultures, were not able to do so in
progenitor-enriched cultures.
DISCUSSION
Using the highly speciﬁc CB1R antagonist AM251 in mixed spinal
cord cultures containing neurons, glia, and neural progenitors, a
signiﬁcant increase in the number and percentage of immature
neurons was observed in a concentration-dependent and biphasic
manner. The neurogenic response elicited by AM251 was blocked
by the presence of the CB1R agonistsWIN 55, 212-2, orACEA, and
also of TTX. This neurogenic action of AM251 was not observed
in progenitor-enriched cultures, even when AM251 was used in
the presence of the growth medium used in the mixed cultures.
Both in spinal cord slices and in acutely isolated mixed cultures,
those derived from CB1R knock-out (CB1−/−) mice consistently
showed a higher number of cells expressing immature neuronal
markers compared towild type (CB1+/+). This result is indicative
of a higher baseline of constitutive neurogenesis in the spinal cords
of CB1−/− mice. Moreover, AM251 did not further increase the
number and percentage of immature neurons in CB1−/− cul-
tures, demonstrating the speciﬁcity of AM251 for the CB1R in
our observed effect. Therefore, the data from two different rodent
species, using both pharmacology and genetic techniques suggest
that antagonism or absence of CB1R results in enhanced neuronal
differentiation in the adult spinal cord.
The possibility of neuronal activity as a player in neuronal dif-
ferentiation induced by AM251 was investigated by using TTX.
The rationale for these experiments was based on the known
inhibitory effects of CB1Rs at pre-synaptic sites of the CNS by
reducing the probability of neurotransmitter release (Schlicker
and Kathmann, 2001). Therefore, binding of AM251 to CB1Rs on
pre-synaptic sites, or the absence of CB1R (using CB1−/− mice)
could facilitate neurotransmitter release, and therefore modulate
neuronal activity. The proposed change in overall neuronal activ-
ity by AM251 may ultimately enhance neuronal differentiation in
the mixed spinal cord cultures. To test the idea that sodium chan-
nel (Nav)-dependent neuronal activity is necessary for AM251’s
effect in the mixed cultures, we chronically blocked this activity
by using TTX from Day 0 of culture. Because TTX was able to
mostly block the effect of AM251, it is likely that Nav-dependent
neuronal activity is necessary for the neurogenic action of AM251
in the mixed spinal cord cultures. The idea that neuronal activ-
ity and neurotransmitters drive progenitor differentiation is not
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FIGURE 7 | In CB1+/+, but not in CB1−/−cultures, AM251 induces
neuronal differentiation which is blocked by the additionTTX. (A) AM251
(30 nM) signiﬁcantly increased the percentage of DCX(+) cells, which was
blocked by co-treatment with TTX (1μM); *p<0.05, **p< 0.01 with respect
to the control DMSO group at Day 6. (B)The mean number of cells was
determined for Day 0 and for every condition on Day 6. In this experiment
there was a signiﬁcant decrease in total number of cells between Day 0 to
Day 6 for all treatments (*p<0.05; but see Figure 5C and text), there were
no signiﬁcant differences between the control DMSO group and any of the
treated groups at Day 6. (A,B)Twenty random ﬁelds were analyzed per
coverslip; n =3 coverslips; mean+SEM. (C) Images of cultures with different
treatments. Chronic TTX (1μM) does not appear toxic to adult spinal cord
cultures. 10× Objective; Scale bars=10μm. Bottom left panels shows a
DCX(+) cell at a higher magniﬁcation (40× objective). (D,E) AM251 does not
signiﬁcantly change the percentage of DCX(+) cells (D) neither the total
number of cells (E) in CB1−/− spinal cord cultures. Twenty random ﬁelds
were analyzed per coverslip; n =3 coverslips; mean+SEM. (F,G) A total of 10
ﬁelds per each coverslip (n) were analyzed. (F)The percentage of DCX(+) cells
remains unchanged in the presence of the Na+ channel blocker TTX(1μM).
(G)The total number of cells was not signiﬁcantly different among
treatments. Data generated from three CB1−/− mice. In this experiment
there was a signiﬁcant decrease in the total number of cells between Day 0
to Day 6 (**p<0.01; but see Figure 5C and text). For (A–G) we used
One-way ANOVA, Bonferroni post test.
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FIGURE 8 | Neuronal differentiation by AM251 in progenitor-enriched
cultures.The extent of neuronal differentiation induced by AM251 was
tested in progenitor-enriched cultures grown with substrate (attached cells)
because this facilitated and expedited the generation, immunostaining, and
quantiﬁcation of the progenitor cells. First, the freshly dissociated cells were
grown only in the presence of bFGF (20 ng/ml) in Neurobasal A complete
media for 6 days to enrich the culture for progenitors. Following the
enrichment period, bFGF was either kept or removed from the media, and
the effect of AM251(100 nM) was tested by using either the Neurobasal A
complete media or the “growth media” used in the “mixed” cultures (A)
bFGF enriches for Nestin(+) and Nestin(+)/EdU(+) adult spinal cord
progenitor cells. PDL, poly-D-lysine. Right-top panel: an image depicting
cells that incorporated EdU (green), and expressed Nestin (red).
Right-bottom panel: negative control, without primary antibody. Hoechst
3392 labeled nuclei (blue). 20× Objective; Scale bars, 20μm. (B) Relative
amounts of DCX (left panel) and βIII tubulin (right panel) expressing cells
under the various growth conditions. Table below graph indicates with a
small “+” whether a certain drug or growth treatment was present.
*p<0.05; #p<0.01With respect to their corresponding control group
(one-way ANOVA, Bonferroni post test).
new. Local circuitry drives activity dependent neuronal differen-
tiation – reviewed by Vaidya et al. (2007). For example, type 2
progenitor cells in the hippocampus [Nestin(+)/GFAP(−)] are
depolarized by GABA [because of the high (Cl−) inside the prog-
enitors], and this drives the progenitors to differentiate into neu-
rons (Tozuka et al., 2005). These results support the view that the
neurogenic action of AM251 may involve enhancement of spinal
cord neuronal activity.
To our knowledge, this is the ﬁrst study to address and demon-
strate modulation of adult spinal cord progenitor cell fate by the
endocannabinoid system (eCB). Previously, many studies have
addressed the role of the eCB system during development and
adult neurogenesis in the brain. Using rodent models, compo-
nents of the endocannabinoid system were discovered in embry-
onic (Rueda et al., 2002; Aguado et al., 2005), postnatal, and
adult (Aguado et al., 2006; Molina-Holgado et al., 2007) brain
neural progenitor cells. Interestingly, it appears that CB1R acti-
vation promotes neural progenitor proliferation in the brain,
but the role in neurogenesis is less clear. The confusion mostly
results because the separation between the effects on progen-
itor proliferation and neurogenesis has not always been made.
The presence of actively dividing cells within a neurogenic niche
does not necessitate neurogenesis because not all the proliferat-
ing cells become neurons (Jin et al., 2003; Merkle et al., 2004;
Steiner et al., 2004). The study of Jin et al. (2004) suggested
that there was defective neurogenesis in CB1−/− mice com-
pared to CB1+/+ mice, but the authors equated decreased BrdU
(5-Bromo-2-deoxyurdine) incorporationwithdecreasedneuroge-
nesis without quantifying co-expression with neuronal markers.
In another study, CB1R activation was concluded to promote neu-
rogenesis because of increased hippocampal proliferation, even
when there was no net change in the amount of new neurons
(Jiang et al., 2005). However, using NeuN as a neuronal marker
and BrdU as a proliferation marker, several other studies have
demonstrated that treatment with CB1R agonists decreased the
number of these co-labeled hippocampal cells, but increased the
number of BrdU(+)/NeuN(−) hippocampal cells (Rueda et al.,
2002; Aguado et al., 2006; Galve-Roperh et al., 2006) indicative of
Frontiers in Neuroscience | Neuropharmacology January 2012 | Volume 6 | Article 4 | 12
Sideris et al. CB1R antagonism induces neuronal differentiation
increased proliferation without subsequent differentiation toward
a neuronal fate.
Moreover, the numerous eCB system components may affect
the various adult brain progenitor populations differently. In vivo,
CB1Rs and Fatty Acid Amide Hydrolase, the anandamide degrad-
ing enzyme, are highly expressed in type 1, but not in type 2,
hippocampal progenitors (Aguado et al., 2006). Another recent
study demonstrated the exact opposite staining pattern; CB1R
was preferentially expressed in type 2/DCX(+) cells, suggesting
that the receptor may have a role in neuronal differentiation and
migration of the newly formed neuron (Wolf et al., 2010). Though
clariﬁcation through additional studies must be made to reconcile
different interpretations and/or results, these ﬁndings suggest that
there is also a need to consider the separate progenitor populations
to understand how CB1R modulates them in the context of adult
brain neurogenesis.
Cannabinoid 1 receptor may also modulate neurogenesis dif-
ferently under various patho-physiological contexts (Aguado et al.,
2007; Rivera et al., 2011). For example, simultaneous changes in
growth factors obscure the actual neurogenic action of cannabi-
noids. Kainate induced excitotoxicity in vivo lead to an increase
in the number of BrdU(+)/NeuN(+) cells which were reduced
in CB1−/− mice, but this treatment also results in an increase in
the expression of various growth factors (bFGF, BDNF, and EGF)
both in CB1+/+ and in CB1−/− mice (Aguado et al., 2007). As
indicated by the authors, CB1R’s role on neurogenesis appears to
be sometimes difﬁcult to separate from that mediated by growth
factors. Also, AM251 is able to promote neurogenesis in the Sub-
Ventricular Zone of obese, but not normal rats (Rivera et al., 2010).
Compared to the adult brain, the adult spinal cord progenitor
niche is not as well deﬁned. There are progenitor cells scattered
throughout the spinal cord parenchyma and in the central canal
(Johansson et al., 1999; Ohori et al., 2006; Meletis et al., 2008;
Hamilton et al., 2009). The endocannabinoid system has not been
as extensively studied in the spinal cord as it has in the brain.
Only recently have studies demonstrated the presence and crit-
ical roles of the endocannabinoid system in the spinal cord for
the execution of movement and for somatosensory information
processing (Marsicano et al., 2003; Kettunen et al., 2005; Galve-
Roperh et al., 2008; Garcia-Ovejero et al., 2009). Following injury,
neurogenesis in the adult spinal cord remains a challenge mostly
because the spinal cord environment favors glial differentiation
(Barnabe-Heider et al., 2010; Wang et al., 2011). There is some
evidence for neurogenesis [presence of DCX(+)/BrdU(+) cells]
in the intact adult spinal cord,with apreferential dorsal graymatter
distribution and GABAergic phenotype; however, the role of these
immature neurons, and their long term fate are not well under-
stood (Shechter et al., 2007, 2010). We found that the spinal cord
slices derived from CB1−/− mice have a signiﬁcantly higher levels
of DCX(+) cells compared to those derived from the CB1+/+
mice, indicative of enhanced neuronal differentiation in CB1−/−
spinal cords.
Our study has interesting implications for spinal cord injury
because of the potential pharmacotherapeutic interventions with
CB1R antagonists for the replacement of damaged neurons.
Our data also suggest that the elevated levels of endocannabi-
noids that have been previously detected in the adult spinal
cord following injury (Petrosino et al., 2007; Garcia-Ovejero
et al., 2009) could contribute to the non-neurogenic environ-
ment. Moreover, the high levels of DCX (+) cells in the spinal
cords of CB1−/− mice are intriguing. Additional studies are
needed to elucidate the overall distribution and properties of
these cells in vivo as they may be contributing to the hypoalgesic
or hypoactive phenotypes of the knock-out mice (Zimmer et al.,
1999).
Taken together, the results demonstrate, for the ﬁrst time, that
CB1R is present on adult spinal cord-derived Nestin(+) prog-
enitor cells when they are grown under enriching conditions, or
when they are grown in the presence of other spinal cord cells.
Treatment of spinal cord cultures with AM251 induces neuronal
differentiation in a CB1R speciﬁc manner. Neuronal activity is
partly necessary for AM251’s effect, as TTX abrogates the effect on
neuronal differentiation suggestive of neurotransmitter involve-
ment. Interestingly, thiswork is also theﬁrst demonstrationof high
levels of immature neurons in the adult spinal cords from CB1R
knock-out (CB1−/−) mice compared to wild type both in vivo
and in vitro, in accordance with the idea that the presence of CB1R
and its activation with exogenous or endogenous ligands inhibit
the expression of immature neuronalmarkers. Future experiments
will characterize the distribution and properties of the immature
neurons in the CB1−/− spinal cords, and whether CB1R antag-
onists can promote neurogenesis in vivo in normal and injured
spinal cords.
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